XML 43 R32.htm IDEA: XBRL DOCUMENT v3.23.1
Segments (Tables)
3 Months Ended
Mar. 31, 2023
Segment Reporting [Abstract]  
Schedule of Operations and Assets for Operating Segments and Geographic Information Information regarding our operations and assets for our operating segments and the unallocated corporate operations as well as geographic information are as follows:
 For the three months ended March 31,
(In thousands)20232022
Revenue from services:
Pharmaceutical$— $— 
Diagnostics132,368 286,599 
Corporate— — 
$132,368 $286,599 
Revenue from products:
Pharmaceutical$40,383 $36,658 
Diagnostics— — 
Corporate— — 
$40,383 $36,658 
Revenue from transfer of intellectual property and other:
Pharmaceutical$64,826 $5,962 
Diagnostics— — 
Corporate— — 
$64,826 $5,962 
Operating income (loss):
Pharmaceutical$18,955 $(18,108)
Diagnostics(40,007)(43,548)
Corporate(9,542)(10,768)
$(30,594)$(72,424)
Depreciation and amortization:
Pharmaceutical$17,760 $15,402 
Diagnostics8,686 12,412 
Corporate— — 
$26,446 $27,814 
Loss from investment in investees:
Pharmaceutical$(37)$(49)
Diagnostics— — 
Corporate— — 
$(37)$(49)
Revenues:
United States$189,085 $291,808 
Ireland15,846 8,462 
Chile15,541 16,339 
Spain6,110 7,109 
Israel4,594 1,558 
Mexico5,826 3,750 
Other575 193 
$237,577 $329,219 
(In thousands)March 31,
2023
December 31,
2022
Assets:
Pharmaceutical$1,373,982 $1,322,531 
Diagnostics671,875 690,504 
Corporate123,813 154,224 
$2,169,670 $2,167,259 
Goodwill:
Pharmaceutical$314,355 $312,826 
Diagnostics283,025 283,025 
$597,380 $595,851